Frank Sorgi | President and Chief Executive Officer
FLAG Therapeutics

Frank L. Sorgi, Ph.D., MBA, is President, CEO and founder of FLAG Therapeutics. He brings with him 30 years of experience as an entrepreneurial scientist in the field of drug delivery and dosage form design and as a business executive in the biotechnology and pharmaceutical industries. Prior to founding FLAG, Dr. Sorgi served as VP of global science and technology at Patheon, a CDMO, where he was responsible for all early drug development activities from inception through Phase 2 product development. From 2006 to 2011, he served as VP of R+D at DPT Labs, a leading CDMO for liquids and semi-solid dosage forms. At DPT, Dr. Sorgi managed all pre-commercial research and development activities. From 2004 to 2006, he worked at BioMarin as program director of the Orapred franchise and the Aldurazyme joint venture with Genzyme, overseeing all commercial product-related activities. From 1999 to 2004, Dr. Sorgi served in a number of increasingly responsible positions at OPTIME Therapeutics, acting ultimately as president, CEO and board member.  Dr. Sorgi began his career in the 1990's as a leading scientist in the field of non-viral gene therapy, participating in 8 human gene therapy clinical trials. Dr. Sorgi received a Ph.D. in pharmaceutical sciences from the University of Pittsburgh (studying under Professor Leaf Huang) and degrees from Duquesne University, including an M.S. in pharmaceutics, an MBA in business management and a B.S. in pharmacy.